About this course
This learning module is aimed at helping clinicians maximise the effectiveness of MHT while minimising the potential risks across a range of circumstances and scenarios.
The most effective treatment for troublesome symptoms of menopause is still hormone therapy. Body identical hormones are now available which offer a number of clinical advantages. Moreover, drug delivery options are also varied - patch, pill, gel etc so clinicians can work with patients to determine which hormones and which delivery system is best suited to their needs.
Learning Outcomes
- Explain the safety/risk profile of various components of MHT and how to put these risks into a practical perspective
- Describe why body identical hormones represent a clinical advantage over synthetic hormones for MHT
- Increase confidence to prescribe MHT that is suitably tailored to the individual patient
About the Expert
Prof Rod Baber
Rod Baber is Professor of Obstetrics and Gynaecology at The University of Sydney and heads the Menopause Hub at Royal North Shore Hospital in Sydney.
Prof Baber is a life member and Past President of both the Australasian Menopause Society and The International Menopause Society. He is Editor-in-Chief of Climacteric, the journal of The International Menopause Society and is Associate Editor of ANZ Journal of Obstetrics and Gynaecology.
Accredited with the following bodies
This course falls under the following CPD activity type:
1 hour in the Educational Activities category and 1 hour in the Reviewing Performance category.
This activity is proudly supported by an independent educational grant from Theramex
